Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest tumour Stories

2013-02-08 08:25:13

CALGARY, Feb. 8, 2013 /PRNewswire/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC) (NASDAQ: ONCY) today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN(®) in combination with carboplatin and paclitaxel (REO 021). The analysis examined percent best overall tumour changes between pre-treatment and up to six treatment...

Key Process Discovered That Allows Colon Cancer To Metastasize
2012-11-13 10:57:33

Institute for Research in Biomedicine (IRB Barcelona) The study, published in the prestigious journal Cancer Cell, reveals that tumor cells of the colon must form alliances with healthy cells in order to colonize other organs during metastasis A team of 17 researchers, led by scientists Eduard Batlle and Elena Sancho in the Colorectal Cancer Laboratory at the Institute for Research in Biomedicine (IRB Barcelona), have determined that the ability of colon cancer to metastasize lies in...

2012-06-26 14:21:22

MELBOURNE, Australia, June 26, 2012 /PRNewswire/ -- Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY) announces that it has been advised by its development partner, Healthscope Advanced Pathology, that it will commercially launch Circadian's novel technology for aid in the diagnosis of "Cancers of Unknown Primary" (CUP), on Monday July 16 2012 in Australia, New Zealand, Singapore and Malaysia under the brand CUPGUIDE(TM). The diagnostic test method has been developed in collaboration...

2012-03-28 00:10:32

A study led by Dr Janet Shipley from The Institute of Cancer Research (ICR) in London in collaboration with Dr Mauro Delorenzi from the SIB Swiss Institute of Bioinformatics in Lausanne has shown that a simple genetic test could help predict the aggressiveness of rhabdomyosarcoma tumours in children. The test, which should be introduced into clinical practice, would lead to changes in treatment for many patients, allowing some children to escape potentially long-term side-effects whilst...

2012-03-06 11:05:26

Discovered a mechanism explaining how tumor cells spread to nearby organs and structures, initiating metastasis Metastasis is responsible for 90% of deaths in patients with cancer. Understanding the mechanisms responsible for this process is one of the top goals of cancer research. The metastatic process involves a series of steps chained where the primary tumour invades surrounding tissues and ends spreading throughout the body. Ones of the first tissues undergoing metastasis are the...

2012-02-15 21:43:32

Laser light in combination with certain drugs — known as photodynamic therapy — can destroy cancer tumours, but is today used mostly to cure skin cancer. The reason that internal tumours are not treated with the method is that the technology does not exist to check that the precise amount of light is administered. However, software developed by researchers in atomic physics at Lund University in Sweden looks like being able to solve the problem. "I think we are about to see a...

2012-01-26 12:08:09

Researchers at CIC Biogune, the Cooperative Centre for Research into Biosciences and led by Dr. Maria Luz Martinez Chantar, have found a strong relationship between high levels of Hu antigen R (HuR) protein and the malignancy of Hepatocellular Carcinoma, through a novel molecular process in the investigation of this pathology and known as neddylation. The project provides new opportunities for making advances in the quest for personalized therapeutic applications in the treatment for...

2012-01-08 16:30:00

MELBOURNE, Australia, Jan. 8, 2012 /PRNewswire/ -- Circadian Technologies Limited (ASX:CIR, OTCQX:CKDXY) announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre. The Phase 1 study will examine the safety and tolerability of escalating doses of VGX-100 in patients with advanced solid tumours who have no other standard treatment options both as a monotherapy and also...

2011-11-02 11:44:01

Prostate cancers are hungry, growing cells. Now we know how to cut off their food supply thanks to research to be published later this month in Cancer Research–work funded by Movember and the Prostate Cancer Foundation of Australia Researchers at the Centenary Institute in Sydney have discovered a potential future treatment for prostate cancer–through starving the tumour cells of an essential nutrient they need to grow rapidly. Their work, with human cells grown in the lab,...

2011-10-31 08:50:00

MELBOURNE, Australia, Oct. 31, 2011 /PRNewswire/ -- Circadian Technologies Limited (ASX: CIR, OTCQX: CKDXY) announces that its 100% owned subsidiary, Vegenics Pty Ltd, has received approval for its investigational new drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate clinical trials of VGX-100. The first trial (Phase I) will study VGX-100 in patients with a variety of late stage cancers. "The FDA's acceptance of our IND represents an extremely important...